BiotechTube
Home/Cingulate Therapeutics/Jeffrey S. Ervin
JS

Jeffrey S. Ervin

Chief Commercial Officer

Cingulate Therapeutics

Therapeutic Areas

Central Nervous System (CNS)Psychiatry

Cingulate Therapeutics Pipeline

DrugIndicationPhase
CTx-1301Attention-Deficit/Hyperactivity Disorder (ADHD)Phase 3
CTx-1302Attention-Deficit/Hyperactivity Disorder (ADHD)Phase 3
CTx-2103Generalized Anxiety Disorder (GAD)Phase 2

Leadership Team at Cingulate Therapeutics

SJ
Shane J. Schaffer
Chairman & Chief Executive Officer
CT
C. Thomas Amick
Co-Founder, President & Chief Operating Officer
MB
Matthew Brams
Chief Medical Officer
LP
Louise P. Short
Chief Financial Officer
View full Cingulate Therapeutics profile